Project Grant R01CA290401

Award Date 4/15/25
Completion Date 3/31/30
Dollars Obligated $714K
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $659,936 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support a comprehensive study on racial disparities in oral cavity squamous cell carcinoma (OSCC) between African American (AA) and European American (EA) patients. The key products and services to be delivered include: Conducting multi-scale analyses of 163 AA-OSCC and 836 EA-OSCC cases to evaluate clinical,...
This $466,370 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to investigate racial disparities in lung cancer treatment and survival among Black non-small cell lung cancer (NSCLC) patients. The primary objectives are to: 1) Determine racial differences in receipt of cancer treatments, time to first treatment, number of treatment cycles, and dose intensity for NSCLC patients; 2) Assess the...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $370,834.00 to Temple University to conduct research examining racial disparities in the molecular and cellular heterogeneity of the esophageal mucosa and its impact on esophageal cancer incidence. The goal is to use single-cell RNA sequencing to compare esophageal tissue samples from African American/Black and Caucasian subjects, both with and without esophageal tumors. This...
The federal project grant award R21CA290334, titled "Ethnicity-Driven pfERNAs in African American Health Disparities in Lung Cancer", was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The $589,459 grant supports research to identify an African American-specific pfRNA (AA-pfRNA) that is induced during lung cancer progression and could be a therapeutic target to inhibit the evolution of lung pre-neoplasia to...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $415,257 to the University of Virginia to conduct research aimed at identifying epigenetic and transcriptomic drivers of racial disparities in colorectal cancer risk and site-specific tumor development. The key products and services to be delivered under this 2-year award include: Identifying site-specific DNA methylation-associated gene expression signatures across different...
This five-year Project Grant award of $1,027,816 from the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports research to examine the impact of structural racism on mutational signatures and outcomes in African American patients with non-small cell lung cancer (NSCLC). The research aims to: Determine how exposure to structural racism factors like air pollution and residential segregation are linked to differences in the types and...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund research to develop a machine learning-based model that can accurately predict the presence of aggressive tissue phenotypes in head and neck squamous cell carcinoma (HNSCC). The $168,610 award, effective from April 2025 to March 2028, will be led by Dr. Yingci Liu at Rutgers, The State University of New Jersey. The...
The National Cancer Institute (NCI) awarded a $200,000 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, awarded on September 15, 2023, supports research to develop novel therapeutic approaches to remediate radiotherapy-induced bone necrosis in oropharyngeal cancer patients, particularly among African-American populations who...
This Project Grant award, valued at $496,567 and awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on June 1, 2024, will support research to develop, validate, and implement advanced computational tumor phenotyping techniques to characterize head and neck squamous cell carcinoma (HNSCC) at multiple biological levels. The research involves high-throughput analysis of quantitative features from radiology images (radiomics) and digital pathology images...
The National Cancer Institute awarded a $398,895 Project Grant (CFDA 93.396) to Keliomics, Inc., a minority-owned small business based in Portland, Oregon. The grant funding supports research to engineer ex vivo breast tumor models using human breast tissue, with the goal of addressing racial disparities in survival rates for HR-/ERBB2+ breast cancer. The key products and services to be delivered under this phase I research grant include identifying the specific conditions required to generate...

This Project Grant award, provided by the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program, aims to investigate the biological mechanisms driving racial disparities in outcomes for head and neck cancer, particularly among Black patients. The $714,062 award will fund two main objectives over a period of 5 years:

  1. Developing a tailored RNA prognostic model to enhance survival predictions for early-stage oral cancer in Black populations, by identifying gene expression signatures associated with disease progression.

  2. Examining the role of long non-coding RNAs at the 8q24.21 genomic locus in modulating tumor aggressiveness, especially in Black patients who are more likely to have amplification at this locus. The research will explore how this amplification impacts tumor proliferation, histopathology, gene expression, and progression, with a focus on the CD44-Hippo signaling axis for potential personalized treatment strategies.

The proposed research aims to bridge the survival gap, advance the understanding of oral cancer biology in patients of African ancestry, and lead to better-targeted therapies and improved prognostic tools.

Generated 4/29/25, 2:09 AM